Ipilimumab Injection

DRUG5 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University Hospital, Strasbourg, France, NYU Langone Health, Federation Francophone de Cancerologie Digestive, Wu Wenming

Conditions

HCC - Hepatocellular CarcinomaMelanomaMelanoma (Skin)MesotheliomaMetastatic CancerMetastatic TumorPancreatic CancerUnresectable Melanoma

Phase 1

Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis

CompletedNCT03949153

University Hospital, Strasbourg, FranceMelanoma (Skin)

Start: 2019-08-16End: 2022-03-18Updated: 2025-10-01

Phase 2

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Active, not recruitingNCT03918252

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMesothelioma

Start: 2019-10-02End: 2027-06-30Updated: 2025-06-26

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

RecruitingNCT05428007

NYU Langone HealthMelanoma, Unresectable Melanoma

Start: 2023-02-02End: 2028-02-29Target: 105Updated: 2026-01-05

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

CompletedNCT05665348

Federation Francophone de Cancerologie DigestiveHCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor

Start: 2023-03-09End: 2025-05-12Updated: 2026-03-09

Unknown Phase

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

RecruitingNCT06353646

Wu WenmingPancreatic Cancer

Start: 2024-03-12End: 2026-12-01Target: 28Updated: 2026-02-13

Related Papers

Abstract 6453: Serum pharmacodynamic biomarkers of IPI/NIVO/RELA plus sarilumab in Stage III-IV melanoma: Stage 1 results of a Simon Phase II trial (NCT05428007)

Cancer Research2026-04-03

Abstract 4724: Elevated plasma trimethylamine-N-oxide (TMAO) levels correlate with better clinical and molecular responses in immunotherapy-treated resectable gastroesophageal cancer and pleural mesothelioma

Cancer Research2026-04-03

Abstract 1129: Analytical and clinical sensitivity of tumor-informed and tumor-naïve ctDNA residual disease detection during neoadjuvant immune checkpoint inhibition in resectable cancers

Cancer Research2026-04-03

Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses

Nature Medicine2025-09-085 citations

A phase II study of the interleukin-6 (IL-6) receptor blocking antibody sarilumab (Sari) in combination with ipilimumab (Ipi), nivolumab (Nivo) and relatlimab (Rela) in patients with unresectable stage III or stage IV melanoma.

Journal of Clinical Oncology2025-05-285 citations

Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2024-06-011 citations

Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial.

2023-02-1618 citations

Trial in progress: Neoadjuvant immune checkpoint blockade in resectable malignant pleural mesothelioma.

Journal of Clinical Oncology2020-05-201 citations